NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM4340570 Query DataSets for GSM4340570
Status Public on Apr 03, 2020
Title PBMC total RNA-late convalescent Lyme disease subject 3
Sample type RNA
 
Source name Peripheral blood mononuclear cells (PBMCs)
Organism Homo sapiens
Characteristics disease state: Late convalescent Lyme disease (6 months following initiation of antibiotic regimen)
Treatment protocol Not applicable; primary human cells were processed immediately after collection from subjects.
Growth protocol Not applicable; primary human cells were processed immediately after collection from subjects.
Extracted molecule total RNA
Extraction protocol Venous blood was collected directly into BD-Vacutainer CPT tubes (Becton Dickinson, Franklin Lakes, NJ). Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation, according to the manufacturer’s protocol, no later than three hours after blood collection. PBMCs were washed with Hank’s Balanced Salt Solution without calcium, magnesium or phenol red (Gibco-BRL, Grand Island, NY), and RNA was isolated immediately thereafter under RNase-free conditions using the Purescript total RNA isolation kit (Gentra, Minneapolis, MN) or the Ambion ToTALLY RNA isolation kit (Life Technologies, Grand Island, NY), according to the manufacturers’ instructions. Contaminating DNA was removed using the DNA-free kit (Ambion, Austin, TX). RNA was eluted in 20 l RNase/DNase-free water and stored at -80°C after the addition of 32 U of RNase inhibitor (Promega, Madison, WI). RNA integrity was assessed by electrophoresis using an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA) prior to cDNA synthesis for microarray hybridization. Samples having an RNA integrity number below 6 were excluded from further analysis.
Label biotin
Label protocol Between 5 and 20 ng of total RNA from each PBMC sample was used to generate high fidelity cDNA using the Ovation RNA amplification system (NuGEN Technologies, Inc., San Carlos, CA), according to the manufacturer’s protocol. The amplified cDNA was fragmented to 50-100 nucleotides and labeled with biotin using standard Affymetrix protocols.
 
Hybridization protocol cDNA was hybridized to the Affymetrix GeneChip.HG-U219 high-density oligonucleotide array (Affymetrix, Santa Clara, CA). Following hybridization, arrays were stained with streptavidin-phycoerythrin and washed in an Affymetrix fluidics module using standard Affymetrix protocols.
Scan protocol The detection and quantitation of target hybridization was performed using a GeneArray Scanner 3000 (Affymetrix).
Description Gene expression data from PBMCs of subjects with late convalescent (6 months after initiation of antibiotics) Lyme disease
Data processing Microarray data were analyzed using GeneSpring GX14.9 software (Agilent Technologies, Santa Clara, CA). Raw expression values in CEL file format were normalized by robust multi-array analysis (RMA) and quantile normalization, filtered to include only those with intensity values above the 20th percentile, and baseline transformed to the median of all samples. Statistical analysis was performed using a one-way ANOVA with Benjamini-Hochberg multiple testing correction to reduce false positives. Differentially expressed transcripts, defined as those having a P-value of <0.05 and a fold change of at least 2 relative to the healthy donor group, were subjected to hierarchical clustering and principal component analysis. A generic predictive modeling framework was developed and applied to two comparisons: acute LD (n=28) versus healthy donors (n=21), and acute LD versus 6 month convalescent LD (n=10). In the first step, the distribution of the gene expression variance across all experimental groups was computed, and genes with variance at or above the 90th percentile were identified. This threshold is a parameter of the framework and can be appropriately set based on the variance distribution in a considered cohort of samples. In the second step, expression data containing the top 10% of variance in each experimental group were subjected to iterations (n = 50) of random forest analysis. An importance value for each gene was generated following each iteration of random forest analysis, and a final importance value for each gene was computed by averaging the importance values across all 50 iterations. Averaged importance values were used to rank all top selected genes. Finally, for each experiment, leave-one-out predictive modeling was performed and tested using incrementally expanding sets of the most significant genes (top 20 through top 2004) to assess the changes of accuracy performance across different sets of predictors.
 
Submission date Feb 26, 2020
Last update date Apr 03, 2020
Contact name Mary Petzke
E-mail(s) mary_petzke@nymc.edu
Organization name New York Medical College
Department Microbiology and Immunology
Lab BSB 306
Street address 15 Dana Road
City Valhalla
State/province NY
ZIP/Postal code 10595
Country USA
 
Platform ID GPL13667
Series (1)
GSE145974 Global transcriptome analysis identifies a signature for early disseminated Lyme disease and its resolution

Data table header descriptions
ID_REF
VALUE log2 normalized intensity values

Data table
ID_REF VALUE
AFFX-DapX-5_at -0.059096098
AFFX-DapX-M_at 0.14751387
AFFX-DapX-3_at 0.13462019
AFFX-LysX-5_at 0.019556284
AFFX-LysX-M_at 0.017107725
AFFX-LysX-3_at 0.033723593
AFFX-PheX-5_at -0.20226932
AFFX-PheX-M_at 0.08998513
AFFX-PheX-3_at -0.02316928
AFFX-ThrX-5_at 0.08180499
AFFX-ThrX-M_at -0.007986546
AFFX-ThrX-3_at 0.5067527
AFFX-TrpnX-5_at 0.452132
AFFX-TrpnX-M_at 0.47102094
AFFX-TrpnX-3_at -0.17149115
AFFX-r2-Ec-bioB-5_at 0.6901798
AFFX-r2-Ec-bioB-M_at 0.7225199
AFFX-r2-Ec-bioB-3_at 0.7452936
AFFX-r2-Ec-bioC-5_at 0.5566702
AFFX-r2-Ec-bioC-3_at 0.6566677

Total number of rows: 49386

Table truncated, full table size 1191 Kbytes.




Supplementary file Size Download File type/resource
GSM4340570_LATE_CONV-3.CEL.gz 2.0 Mb (ftp)(http) CEL
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap